Drug

InnoCare's Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China's First BTD‑Designated BCL2 Inhibitor
Clinical trial approval / initiationHKG: 9969

InnoCare’s Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China’s First BTD‑Designated BCL2 Inhibitor

InnoCare Pharma (HKG: 9969; SHA: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Center for Drug Evaluation (CDE) of China's National…

Laekna's LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

Laekna’s LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CancerClinical trial approval / initiation

Konruns Pharma’s KC1036 Wins NMPA Approval – Dual‑Target VEGFR2/AXL Inhibitor Enters IO Combination Trials

ADC / XDCBiokin Pharmaceutical

Sichuan Biokin’s CD33 ADC BL-M11D1 Wins NMPA Approval – Expands into Myelodysplastic Syndromes

China Medical SystemClinical trial approval / initiation

CMS’s CMS-D008 Wins NMPA Approval – INHBE siRNA Targets Fat‑Selective Weight Loss

Sihuan Pharma's Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label
CancerHKG: 0460

Sihuan Pharma’s Bireociclib Wins NMPA Approval for First‑Line HR+/HER2‑ Breast Cancer – CDK2/4/6 Inhibitor Expands Label

Show More